1331 related articles for article (PubMed ID: 19481021)
1. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
[TBL] [Abstract][Full Text] [Related]
2. Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase.
Sadoni S; Kaczmarek I; Delgado O; Schmöckel M; Reichart B; Meiser B
Transplant Proc; 2007 Mar; 39(2):558-9. PubMed ID: 17362781
[TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
4. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
Wissing KM; Unger P; Ghisdal L; Broeders N; Berkenboom G; Carpentier Y; Abramowicz D
Transplantation; 2006 Sep; 82(6):771-8. PubMed ID: 17006324
[TBL] [Abstract][Full Text] [Related]
5. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
White M; Haddad H; Leblanc MH; Giannetti N; Pflugfelder P; Davies R; Isaac D; Burton J; Chan M; Azevedo E; Howlett J; Ignaszewski A; Busque S; Cantarovich M; Ferguson R; Genest J; Ross H
J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605
[TBL] [Abstract][Full Text] [Related]
6. Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study.
Panichi V; Manca-Rizza G; Paoletti S; Taccola D; Consani C; Sbragia G; Mantuano E; Marchetti V; Carpi A; Barsotti G
Biomed Pharmacother; 2006 Jun; 60(5):249-52. PubMed ID: 16740374
[TBL] [Abstract][Full Text] [Related]
7. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
Crespo-Leiro MG; Paniagua MJ; Marzoa R; Grille Z; Naya C; Flores X; Rodriguez JA; Mosquera V; Franco R; Castro-Beiras A
Transplant Proc; 2008 Nov; 40(9):3060-2. PubMed ID: 19010194
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe in heart transplantation: initial experience.
Moro J; Almenar L; Martínez-Dolz L; Izquierdo M; Agüero J; Sánchez-Lazaro I; Ortiz V; Salvador A
Transplant Proc; 2007 Sep; 39(7):2389-92. PubMed ID: 17889199
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
[TBL] [Abstract][Full Text] [Related]
12. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.
Taylor PJ; Kubler PA; Lynch SV; Allen J; Butler M; Pillans PI
Ann Pharmacother; 2004 Feb; 38(2):205-8. PubMed ID: 14742751
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
Aliabadi AZ; Mahr S; Dunkler D; Grömmer M; Zimpfer D; Wolner E; Grimm M; Zuckermann AO
Transplantation; 2008 Dec; 86(12):1771-6. PubMed ID: 19104420
[TBL] [Abstract][Full Text] [Related]
14. Supratherapeutic response to ezetimibe administered with cyclosporine.
Koshman SL; Lalonde LD; Burton I; Tymchak WJ; Pearson GJ
Ann Pharmacother; 2005 Sep; 39(9):1561-5. PubMed ID: 16030077
[TBL] [Abstract][Full Text] [Related]
15. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
Brown AS; Bakker-Arkema RG; Yellen L; Henley RW; Guthrie R; Campbell CF; Koren M; Woo W; McLain R; Black DM
J Am Coll Cardiol; 1998 Sep; 32(3):665-72. PubMed ID: 9741509
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients.
Manzarbeitia C; Reich DJ; Rothstein KD; Braitman LE; Levin S; Munoz SJ
Liver Transpl; 2001 Feb; 7(2):93-9. PubMed ID: 11172391
[TBL] [Abstract][Full Text] [Related]
17. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
Puccetti L; Bruni F; Bova G; Cercignani M; Palazzuoli A; Console E; Auteri A; Pasqui AL
Nutr Metab Cardiovasc Dis; 2001 Dec; 11(6):378-87. PubMed ID: 12055702
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine.
Vanhaecke J; Van Cleemput J; Van Lierde J; Daenen W; De Geest H
Transplantation; 1994 Jul; 58(1):42-5. PubMed ID: 8036706
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of atorvastatin in heart transplant recipients.
Patel DN; Pagani FD; Koelling TM; Dyke DB; Baliga RR; Cody RJ; Lake KD; Aaronson KD
J Heart Lung Transplant; 2002 Feb; 21(2):204-10. PubMed ID: 11834348
[TBL] [Abstract][Full Text] [Related]
20. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
Farsang C; Athyros V; Gaw A;
Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
